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Introduction   
Newly occurring viral diseases have a huge effect on 
community health in recent years. During past decades, 
many new viral outbreaks have been documented in the 
various parts of the Globe [1]. These outbreaks were 
owing to known viral agents like Crimean Congo 
haemorrhagic fever, Ebola virus disease as well as Nipah, 
Lassa fever, Marburg, Middle East respiratory syndrome, 
coronavirus diseases, Rift Valley fever and severe acute 
respiratory syndrome [2]. WHO has designated Zika, 
thrombocytopaenia syndrome and chikungunya as 
'serious' diseases. These viral diseases are responsible for 
extensive mortality, morbidity and great economic loss 
throughout the world[3]. Yet older viruses like influenza 
are able to reemerge and cause current threats of the 
epidemic and pandemic [4]. These viruses infecting 
humans via direct contact or through infected animals. 
NiV infection is a recently occurring zoonosis that causes 
severe disease in mammals. Fruit bats of the genus 
Pteropus (Family Pteropodidae ) are the main host for 
NiV [5]. In 1998 Kampong Sungai Nipah (Malaysia) the 
first case of NiV was identified in pigs as intermediate 
hosts [6].  According to WHO research and development 
blueprint, NiV infection has high priority disease until no 
medication or vaccines is available for this lethal illness 
[7]. Supportive care is the preliminary treatment of NiV. 
Although NiV reported only a few epidemics the 
causalities were very high among the humans and 
animals. Almost 70 - 100% infected people die due to 
NiV epidemics as this is very serious public health 
concern [8]. This review will be useful to create 
awareness of NiV infection and save lives of human 
beings.  
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Etiology 
Nipah virus from the genus Henipavirus 
(Paramyxoviridae). Nipah virus name came from the 
Malaysian village infection where the first case was 
reported. Bats do not show symptoms but only carriers of 
NiV and infected bats shed virus through their excretions 
and secretions products like excreta, urine semen and 
saliva [9]. Through coughing NiV is widely spread 
amongst pigs.   Direct contact from infected pigs, bats and 
humans transmit NiV infection to human beings. In India 
and Bangladesh this serious infection transmitted directly 
from humans to humans through contact with infected 
humans and caused outbreaks [10]. In 2001, 75% hospital 
employees and visitors in Siliguri in India, transmission 
of NiV from hospitalized patients were reported. In 
Bangladesh, Around 50 % of cases from 2001 to 2008 
were amongst caretakers of the NiV infected patients 
[10]. In 2001, an outbreak in Meherpur in Bangladesh 
found that persons who stayed with infected patients or 
cared for them were more possible to become infected 
with NiV [11].  
Structure of Nipah Virus 
Hendra virus and Cedar virus have a close resemblance to 
the newly formed genus Henipavirus i.e. Nipah virus. The 
diameter of Henipavirus family is 40 to 600 nm [12]. 
Negative sense single-stranded RNA and a linear 
ribonucleoprotein (RNP) comprises of the core of a 
virion. The three important proteins included in RNP. 
Nucleocapsid proteins are highly bound to the various 
nucleotides of the RNA strand (Figure 1) [13]. For 
formation of capsid structure, the Nucelocapsid proteins 
are the principal protein available. Phosphoproteins and 
polymerase proteins are also bound to the RNA and RNA 
polymerase in transcribing RNA to mRNA to 
antigenomic RNA. The virion is covered by a traditional 
lipid bilayer and also spiked with fusion and receptor-
binding glycoproteins [14]. The release of the contents of 
the virion produces fusion proteins. The fusion proteins 
are responsible for fusing the viral membrane to the host 
membrane triggering.  
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Abstract 
Nipah virus (NiV) is a pathogenic paramyxovirus that has been responsible for sporadic outbreaks of respiratory and 
encephalitic disease in tropical countries. Elevated case mortality rate has also been connected with recent outbreaks in 
India (Kerala), Malaysia and Bangladesh. The virus generally infects animals like pigs and bats, but they do not show any 
symptoms of NiV.  The mortality rate in NiV infected humans is more as compared to other mammals. The patient 
usually shows no symptoms to headache fever, cough, dyspnea, confusion and more consequences lead to a coma. 
Although there are no drugs or vaccines available against this severe disease, precaution and awareness reduce the risk of 
NiV-infection. This review will be helpful to save the life of people and decrease death by NiV-infection outbreak. 
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Clinical Spectrum and laboratory diagnosis 
Clinical Signs: 
Although some Nipah virus infections can be 
asymptomatic or mild, most recognized clinical cases 
have been characterized by respiratory disease and/or 
acute neurological signs. The initial symptoms are flu-
like, with fever, headache, sore throat and myalgia [16]. 
Nausea, vomiting and a nonproductive cough may also be 
seen. This prodromal syndrome may be followed by 
encephalitis, with symptoms such as disorientation, 
drowsiness, signs of brainstem dysfunction, convulsions, 
coma and other signs. Encephalitis and seizures occur in 
complicated cases leading to coma within 2 to 4 days 
[17,18]. Segmental myoclonus was common in patients 
with encephalitis in Malaysia, and cases of meningitis, as 
well as encephalitis, were documented in the Philippines 
[17]. NiV infections in few patients emerge as respiratory 
diseases, like atypical pneumonia or acute respiratory 
distress syndrome. These patients may or may not show 
neurological signs. Renal impairment, Septicemia, 
bleeding from the gastrointestinal tract and other 
complications are observed in severely ill patients [19]. 
Survivors of encephalitis may have mild to severe 
residual neurological deficits, or in a vegetative state. 
Some people infected with Nipah virus develop recurred 
encephalitis or late-onset encephalitis, months or years 
afterward. The clinical signs usually develop acutely, with 
symptoms that may include headache, fever, seizures and 
focal neurological signs. Some cases are life-threatening. 
The incubation period of NiV infection is about 4 to 14 
days and also seen some patients up to 45 days [20]. 
 
Figure 1: Structure of Henipavirus [15] 
Diagnosis: 
Oro-pharyngeal/nasal swabs, urine, and serum can be 
used for isolation from live animals, while the brain, lung, 
kidney, and spleen samples can be used postmortem [21]. 
If possible, urine should also be collected for analysis. As 
per biosecurity protocols, stringent use of personal 
protective equipment should be used when sampling with 
suspected NiV infection. 
Detection of Nucleic Acids, Virus, or Antigens: 
Virus separation should be done for exact diagnosis in the 
affected area with a newly suspected epidemic. The 
oropharyngeal and nasal swabs in 2 days post-infection 
are collected for NiV detection. Diagnosed NiV infected 
person goes on shedding virus up to 21 days post-
infection [4]. A cytopathic effect is generally observed 
within 2 to 3 days, but multiple passages of 5 days each 
are recommended before confirming that a sample is NiV 
negative. Quantitative real-time polymerase chain 
reaction primers and probes are developed for the 
identification of the nucleocapsid gene of NiV [14, 22].  
Immunohistochemistry can be used to detect NiV. The 
nucleocapsid protein antigen is generally targeted. With 
the help of immunohistochemistry detection of 
phosphoprotein, an antigen is also possible, although 
nucleocapsid protein antigen is expressed in larger values 
than phosphoprotein antigen and hence it has significant 
diagnostic value.  
Immunofluorescence can speedily detect NiV but cannot 
distinguish between HeV, since mono-specific antisera to 
characteristic proteins of NiV will cross-react with HeV. 
Negative contrast electron microscopy may be employed 
to identify viral particles.  
Detection of Antibody: 
An indirect enzyme-linked immunosorbent assay 
(ELISA) using recombinant NiV N protein as an antigen 
has been employed as a diagnostic test. Recombinant 
proteins permit use of the ELISA to test samples that have 
been treated to inactivate the virus in biosafety level 
(BSL) 2 diagnostic labs [7].  
Virus neutralization tests (VNT) have been employed for 
high-throughput screening in BSL2 diagnostic 
laboratories using recombinant vesicular stomatitis virus 
(rVSV) expressing NiV fusion protein and glycoprotein 
[13].  
To detect both, antibody inhibition of ephrin-B2 receptor 
binding and antibody binding to recombinant soluble HeV 
or NiV G protein multiplexed microsphere immunoassays 
have been employed. Spectrally distinct microspheres 
determine specific and sensitive quantification and 
distinguish between HeV and NiV antibodies in a sample 
[23].  
Prevention, control and Treatment  
The treatment is limited to supportive care as there are no 
medications or vaccines available against NiV-infection 
to date [24, 25]. After confirmation of diagnosis 
immediately admit the patient in the ICU under close 
monitoring for 24 hours. Treatment on fever and the other 
neurological symptoms should be taken care on priority 
basis in ICU. The symptoms of nausea, vomiting and 
convulsions may be alleviated by Ribavirin [7]. The 
patient should be well hydrated. Preventive measures are 
only option as there are no other alternatives for treatment 
of disease. The following preventive measures are 
recommended [26, 27]. 
1. All fruits that are bitten by infected animals should be 
avoided and also these fruits should not be given to 
farm animals.  
2. Infected people or animals should be kept isolated and 
their movement should be restricted. The instrument 
used by patients should be autoclaved with the use of 
glutaraldehyde solution (2%). Disposable materials 
should be used for the patient.  
3. The alcohol-based solution is recommended for hand 
washing for about 20 seconds. Wearing of N95 mask 
is advised during investigational sampling from 
patient. 
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4. Clean all the utensils used by an infected person with 
an alkaline solution (pH 8.5) and also wash the fruits 
and vegetables with water after adding some amount 
of baking soda or sodium hydrogen carbonate for one 
minute.  
5.  Alkaline detergents should be used for cleaning and 
disinfection of farm animals. 
6. Suspicion of epidemics, the animals should be 
quarantined immediately. Killing and burial or 
incineration of infected animals can be essential to 
reduce the risk of transmission under expert 
supervision. 
7. Avoid contact of body fluids of patients to the 
employees, health care team members and others [28].  
8. If the domestic animals show weakness and runny 
nose, a veterinarian should be consulted urgently. 
9. NiV infected people should not get in close physical 
contact with anyone. 
Conclusion 
Nipah virus infection is a newly developed zoonotic 
disease. Hence public should know about this illness. The 
creation of awareness regarding NiV will be helpful for 
preventing the transmission and occurrence of this 
disease. The clinical signs are headache, fever dizziness 
and vomiting, followed by disorientation, drowsiness and 
mental confusion. There is no particular vaccine and 
medication currently available for either humans or 
animals. The treatment is currently limited to supportive 
care. The knowledge about the preventive measures of 
transmission of disease is the only option available to 
mankind. 
Conflicts of Interest: The authors declare no conflict of 
interest     
References 
[1] Rollin PE. Nipah Virus Disease. Emerg Infect Dis 
[Internet. 2014 Jan 1 [cited 2019 Oct;175–84. 
Available from. Available from: https://
www.sciencedirect.com/science/article/pii/
B9780124169753000133?via%3Dihub [Google 
Scholar] 
[2] Vandali V, Biradar RB. Nipah Virus ( Niv ) 
Infection: A Systematic Review. JOJ Nurse Health 
Care 2018;8(1):1-5. doi: 10.19080/
JOJNHC.2018.08.555729. [Google Scholar] 
[3] Upendrababu V. Nipah Virus Infection, a High 
Priority Disease: History, Facts, Transmission, 
Symptoms, Prevention and Treatment. Int J Biomed 
Sci Eng 2018;6(2):38. Available from: http://
www.sciencepublishinggroup.com/journal/
paperinfo?journalid=259&doi=10.11648/
j.ijbse.20180602.13 doi: 10.11648/
j.ijbse.20180602.13. [Google Scholar] 
[4] Chua KB, Lam SK, Goh KJ, et al. The presence of 
nipah virus in respiratory secretions and urine of 
patients during an outbreak of nipah virus 
encephalitis in Malaysia. J Infect 2001;42(1):40-43. 
Available from: https://linkinghub.elsevier.com/
retrieve/pii/S0163445300907825 doi: 10.1053/
jinf.2000.0782. [Google Scholar] 
[5] Kulkarni DD, Tosh C, Venkatesh G, Senthil Kumar 
D . Nipah virus infection: Current scenario. Indian J 
Virol 2013;24(3):398-408. Available from: http://
link.springer.com/10.1007/s13337-013-0171-y doi: 
10.1007/s13337-013-0171-y. [Google Scholar] 
[6] Alothman M, Bhat R, Karim AA. Antioxidant 
capacity and phenolic content of selected tropical 
fruits from Malaysia, extracted with different 
solvents. Food Chemistry 2009;115(3):785-788. 
Available from: https://linkinghub.elsevier.com/
retrieve/pii/S030881460801457X doi: 10.1016/
j.foodchem.2008.12.005. [Google Scholar] 
[7] Angeletti S, Lo Presti A, Cella E, Ciccozzi M. 
Molecular epidemiology and phylogeny of Nipah 
virus infection: A mini review. Asian Pacific 
Journal of Tropical Medicine 2016;9(7):630-634. 
Available from: http://linkinghub.elsevier.com/
retrieve/pii/S1995764516301006 doi: 10.1016/
j.apjtm.2016.05.012. [Google Scholar] 
[8] Luby SP. The pandemic potential of Nipah virus. 
Antiviral Research 2013;100(1):38-43. Available 
from: https://linkinghub.elsevier.com/retrieve/pii/
S0166354213001988 doi: 10.1016/
j.antiviral.2013.07.011. [Google Scholar] 
[9] Ross R. The pathogenesis of atherosclerosis: a 
perspective for the 1990s. Nature 1993;362
(6423):801-809. Available from: http://
www.nature.com/articles/362801a0 doi: 
10.1038/362801a0. [Google Scholar] 
[10] Hsu VP, Hossain MJ, Parashar UD, Ali MM, 
Ksiazek TG, Kuzmin I, et al. Nipah virus 
encephalitis reemergence, Bangladesh. Emerg Infect 
Dis. 2004 Dec;10(12 2082;PMCID(12):2082-2087. 
Available from: http://wwwnc.cdc.gov/eid/
article/10/12/04-0701_article.htm PubMed PMID: 
15663842. doi: 10.3201/eid1012.040701. [Google 
Scholar] 
[11] Gurley ES, Montgomery JM, Hossain MJ, et al. 
Person-to-person transmission of Nipah virus in a 
Bangladeshi community. Emerg Infect Dis 2007;13
(7):1031-1037. Available from: http://
wwwnc.cdc.gov/eid/article/13/7/06-
1128_article.htm doi: 10.3201/
eid1307.061128. [Google Scholar] 
[12] Aljofan M, Saubern S, Meyer AG, Marsh G, Meers 
J, Mungall BA. Characteristics of Nipah virus and 
Hendra virus replication in different cell lines and 
their suitability for antiviral screening. Virus Res. 
2009 Jun;142(1-2):92-9. Epub 2009 Jan;PubMed 
Central PMCID(1-2):92-99. Available from: https://
linkinghub.elsevier.com/retrieve/pii/
S0168170209000227 PubMed PMID: 19428741. 
doi: 10.1016/j.virusres.2009.01.014. [Google 
Scholar] 
[13] Yabukarski F, Lawrence P, Tarbouriech N, et al. 
Structure of Nipah virus unassembled nucleoprotein 
in complex with its viral chaperone. Nat Struct Mol 
Biol 2014;21(9):754-759. Available from: http://
www.nature.com/articles/nsmb.2868 doi: 10.1038/
nsmb.2868. [Google Scholar] 
Surana et al.   Public Health concern for a Nipah Virus disease. 
Int. J. Curr. Res. Physiol. Pharmacol. 2019;3(4):8-11. 
 11 
 
[14] Vera-Velasco NM, García-Murria MJ, Sánchez del 
Pino, M. (Manuel), Mingarro I, Martinez-Gil L. 
Proteomic composition of Nipah virus-like particles. 
Journal of Proteomics 2018;172(August):190-200. 
Available from: https://linkinghub.elsevier.com/
retrieve/pii/S187439191730369X doi: 10.1016/
j.jprot.2017.10.012. [Google Scholar] 
[15] Rockx B, Winegar R, Freiberg AN. Recent progress 
in henipavirus research: molecular biology, genetic 
diversity, animal models. Antiviral research 2012 
Aug;95(2):135-49. Available from: https://
linkinghub.elsevier.com/retrieve/pii/
S0166354212001234 doi: 10.1016/
j.antiviral.2012.05.008. [Google Scholar] 
[16] Satterfield BA, Cross RW, Fenton KA, et al. The 
immunomodulating v and W proteins of Nipah virus 
determine disease course. Nat Commun 2015;6
(May):1-15. Available from: http://
www.nature.com/articles/ncomms8483 doi: 
10.1038/ncomms8483. [Google Scholar] 
[17] Health ISP. Nipah Virus Barking Pig Syndrome, 
Porcine Respiratory and Encephalitis Syndrome, 
Porcine Respiratory and Neurologic Syndrome. 
2011:1-9.http://www.cfsph.iastate.edu/Factsheets/
pdfs/nipah.pdf 
[18] Bellini WJ, Harcourt BH, Bowden N, Rota PA. 
Nipah virus: An emergent paramyxovirus causing 
severe encephalitis in humans. J Neurovirol 2005;11
(5):481-487. Available from: http://
link.springer.com/10.1080/13550280500187435 
doi: 10.1080/13550280500187435. [Google 
Scholar] 
[19] Ahmad SB, Tan CT. Nipah encephalitis - an update. 
Med J Malaysia 2014;69(August):103-111. [Google 
Scholar] 
[20] Wong KT, Shieh WJ, Kumar S, et al. Nipah virus 
infection: Pathology and pathogenesis of an 
emerging paramyxoviral zoonosis. Am J Pathol 
2002;161(6):2153-2167. Available from: https://
linkinghub.elsevier.com/retrieve/pii/
S0002944010644938 doi: 10.1016/S0002-9440(10)
64493-8. [Google Scholar] 
[21] Sharma V, Kaushik S, Kumar R, Yadav JP, Kaushik 
S. Emerging trends of Nipah virus: A review. Rev 
Med Virol 2019;29(1):1-6. doi: 10.1002/
rmv.2010. [Google Scholar] 
 
 
 
 
 
 
 
 
 
 
 
[22] Bettio LE, Freitas AE, Neis VB, Santos DB, Ribeiro 
CM, Rosa PB, et al. Guanosine prevents behavioral 
alterations in the forced swimming test and 
hippocampal oxidative damage induced by acute 
restraint stress. Pharmacol Biochem Behav 2014; 
127:7-14. Available from: https://
linkinghub.elsevier.com/retrieve/pii/
S0091305714002767 PubMed PMID: 25316306. 
doi: 10.1016/j.pbb.2014.10.002. [Google Scholar] 
[23] Matthew I. Bonaparte, Antony S. Dimitrov, 
Katharine N. Bossart, Gary Crameri, Bruce A. 
Mungall, Kimberly A. Bishop, Vidita Choudhry, 
Dimiter S. Dimitrov, Lin-Fa Wang, Bryan T. Eaton, 
and Christopher C. Broder. Ephrin-B2 ligand is a 
functional receptor for Hendra virus and Nipah 
virus. PNAS 2005;102(30):10652-10657. [Google 
Scholar] 
[24] Narang R. Nipah virus: Biology, disease, treatment, 
control, and prevention. J Mahatma Gandhi Inst 
Med Sci 2018;23(2):65-8. Available from: https://
doi.org/10.4103/jmgims.jmgims_39_18 doi: 
10.4103/jmgims.jmgims_39_18. [Google Scholar] 
[25] Satterfield BA, Dawes BE, Milligan GN. Status of 
vaccine research and development of vaccines for 
nipah virus. Vaccine 2016;34(26):2971-5. Available 
from: https://linkinghub.elsevier.com/retrieve/pii/
S0264410X16002966 doi: 10.1016/
j.vaccine.2015.12.075. [Google Scholar] 
[26] WHO guideline for Management Prevention and 
Control of Nipah Virus Infection, Institute of 
epidemiology disease control and research, 
Bangladesh, 2016, 31-32 
[27] Wong KT, Shieh WJ, Kumar S, Norain K, Abdullah 
W, Guarner J, Goldsmith CS, Chua KB, Lam SK, 
Tan CT, Goh KJ, Chong HT, Jusoh R, Rollin PE, 
Ksiazek TG, Zaki SR, , Group NVPW. Nipah virus 
infection: pathology and pathogenesis of an 
emerging paramyxoviral zoonosis. Am J Pathol. 
2002 Dec;161(6 2153;PMCID. PubMed PMID: 
12466131. doi: 10.1016/S0002-9440(10)64493-
8. [Google Scholar] 
[28] Chadha MS, Comer JA, Lowe L, et al. Nipah virus-
associated encephalitis outbreak, Siliguri, India. 
Emerg Infect Dis 2006;12(2):235-240. Available 
from: http://wwwnc.cdc.gov/eid/article/12/2/05-
1247_article.htm doi: 10.3201/
eid1202.051247. [Google Scholar] 
Surana et al.   Public Health concern for a Nipah Virus disease. 
Int. J. Curr. Res. Physiol. Pharmacol. 2019;3(4):8-11. 
